News

Should You Buy Gilead Stock At $110?
Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...
Here’s what everyone should know about this new HIV prevention shot
Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...
Stocktwits on MSN1d
Gilead Earns Analyst Praise As FDA Clears Yeztugo For Biannual HIV Prevention
Gilead Sciences garnered investor and analyst focus after the U.S. FDA approval of Yeztugo, or lenacapavir, the company’s ...
Fierce Pharma2d
FDA signs off on Gilead's landmark long-acting PrEP med, signaling new era in HIV prevention
With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...
Morningstar2d
Gilead Sciences Inc GILD
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The BMJ1d
“Hard to justify” $28 000 price tag for breakthrough HIV prevention treatment, says UN agency
A United Nations agency has urged the pharmaceutical company Gilead Sciences to lower the price of the long acting antiviral treatment lenacapavir following the US Food and Drug Administration (FDA)’s ...
CSRWire2d
Gilead Researcher Awarded the AAAS Mani L. Bhaumik Breakthrough of the Year Award
Gilead has been a leader in HIV innovation for decades. Now, we're proud to share that one of our researchers, Moupali Das, ...